Patient Access

As GLP-1 therapies reshape obesity care, Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, argues that lasting progress depends on targeting metabolic health, not just the number on the scale.

FDA has expanded Capvaxive's indication to high-risk children and adolescents aged 2 through 17 who have completed a primary pneumococcal series, making it the only conjugate vaccine in the U.S. specifically studied and approved for this population.

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains what sets his company's obesity strategy apart in an increasingly crowded field.

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, notes how the real obstacle in obesity care isn't how a drug is delivered, it's whether patients stay on treatment long enough to achieve lasting metabolic health.

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, argues the field must evolve beyond the scale, measuring success not just in pounds lost, but in visceral fat reduction, liver health, and preserved muscle mass.

Polaryx’ chief medical officer Lisa Bollinger explains the struggles finding ways to reduce patient costs for gene therapies for rare diseases.

Eli Lilly and Company notes that the approval of an every-8-week maintenance dose of lebrikizumab offers sustained atopic dermatitis control with fewer annual injections.

The framework’s key considerations for pharma brand managers.

Model N Senior Vice President Jesse Mendelsohn explores the hidden costs and realities of PBM-driven drug pricing and the growing challenges manufacturers face in ensuring contract compliance, formulary access and reimbursement accuracy.

Eli Lilly moves to deny 340B discounts to hospitals refusing to submit claims data under its documentation policy, escalating a months-long standoff with the American Hospital Association and prompting calls for federal intervention.

Ascidian Therapeutics has entered a global research and licensing deal with Eli Lilly to develop RNA exon-editing therapies for monogenic kidney diseases, a class of genetic conditions with an unmet need for treatment.

FDA has issued a Complete Response Letter to Cingulate’s ADHD candidate CTx-1301 over manufacturing-related deficiencies, delaying approval of the once-daily therapy while leaving its clinical safety and efficacy profile unchallenged.

FDA approves Shionogi’s Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy, marking a major milestone for Covid-19 prevention treatments.

CVS Health is restoring coverage of Eli Lilly’s Zepbound and adding oral obesity drug Foundayo to its formulary, signaling shifting payer dynamics as lower-cost GLP-1 therapies expand access for patients.

FDA approves Gilead’s Hepcludex as the first treatment for chronic hepatitis delta virus in the U.S., marking a major milestone for a severe liver disease with limited therapeutic options.

FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for first-line metastatic triple-negative breast cancer, expanding treatment options for patients ineligible for PD-1/PD-L1 inhibitor therapy.

New partnerships from Gilead Sciences and Johnson & Johnson highlight how healthcare companies are using collaborations to expand global disease initiatives and accelerate development of AI-enabled healthcare infrastructure.

Lower-cost oral obesity drugs from Novo Nordisk and Eli Lilly are drawing patients away from compounded GLP-1 therapies, according to interviews with U.S. doctors from Reuters, signaling shifting market dynamics as branded oral treatments expand access and intensify competition in the obesity space.

Toragen CEO Sandra Coufal, MD, discusses why the company is targeting HPV’s overlooked E5 protein, positioning its small-molecule therapy as a potential complement to checkpoint inhibitors like Keytruda across HPV-driven cancers.

The Trump administration has expanded TrumpRx to include more than 600 generic medications and integrated price comparison tools with partners including Amazon Pharmacy, Cost Plus Drugs, and GoodRx, broadening the platform beyond its original focus.

FDA approved AstraZeneca’s Fasenra for hypereosinophilic syndrome in patients aged 12 and older, expanding the IL-5 receptor-targeting therapy into a third eosinophil-driven disease with limited treatment options.

How existing technologies and approaches such as targeted AI deployment can help make prior authorization workflows more efficient.

FDA has approved BeOne Medicines’ Beqalzi for relapsed or refractory mantle cell lymphoma and Taiho Oncology’s Inqovi plus venetoclax for newly diagnosed acute myeloid leukemia, expanding treatment options for patients with difficult-to-treat blood cancers.

In an exclusive Q&A, Dean Erhardt discusses how fragmented onboarding processes delay therapy starts, along with noting how poor communication, limited visibility, and system misalignment is driving patient disengagement.

FDA has approved Partner Therapeutics’ Bizengri for NRG1 fusion-positive cholangiocarcinoma, expanding precision oncology options for a rare subset of gastrointestinal cancer patients with limited targeted treatment alternatives.